LinkedIn IconTwitter Icon

28-29 November 2018, Berlin

Day One
Wednesday 28 November

Day Two
Thursday 29 November

07.50
Registration and Networking

08.20
Chairs Opening Remarks

  • Zhen Su Senior Vice President & Chief Medical Officer, Merck KGaA

Understanding How Immuno-Oncology is Changing the Oncology Landscape

08.30
Keynote – Evaluating How the Immuno-Oncology Therapies Have Changed the Standard of Care in Oncology & What This Means for the Field & Patients

  • Zhen Su Senior Vice President & Chief Medical Officer, Merck KGaA

09.00
Keynote – Adenosine-mediated Immunosuppression: Escape From First Generation Checkpoint Inhibitors

  • Kris Sachsenmeier Associate Director, Translational Science, IMED Oncology, AstraZeneca

09.30
Enabling Multidimensional Biomarker Discovery: Interrogating the Tumor, its Microenvironment, and Neoantigens with ACE ImmunoID

  • Erin Newburn Associate Director, Field Applications Scientist, Personalis

10.00
Speed Networking & Morning Refreshments

Developing Reliable, Translatable & Meaningful Preclinical Models

11.15
Preclinical Mouse Models to Support the Rapid Development of Innovative Immuno-Oncology Therapeutics

  • Reece Marillier Research Scientists, In Vivo Pharmacology, iTeos Therapeutics

11.45
Roundtable session: What Makes a Good Model? Contrasting Available Preclinical Modelling Approaches to Enhance Translation into the Clinic

12.30
Lunch & Networking

Cancer Immunity Cycle Stages 1-3 Release of Antigen, Priming & Activation

13.30
Therapeutic Modulation of the Microenvironment of Tumour-Draining Lymph Nodes Through Local Administration of TLR Agonists or Immune Checkpoint Inhibitors

  • Tanja de Gruijl Professor, Translational Tumor Immunology & Head of Immunotherapy Lab, VU University Medical Center

14.00
Two ACTive Immunotherapies (TACTI): Results of a Phase I Trial With Metastatic Melanoma Patients (TACTI-mel) Treated With a Soluble LAG-3 Receptor (LAG-3lg Or Eftilagimod Alpha) as an Antigen Presenting (APC) Activator Combined with Pembrolizumab

14.30
Afternoon Break & Refreshments

15.00
Presentation Details to be Confirmed

  • Markus Zettl Director, Immuno-Oncology, Pieris Pharmaceuticals

15.30
PI3Kδ: A New Era in Immuno-Oncology

16.00
Chair’s Closing Remarks

  • Zhen Su Senior Vice President & Chief Medical Officer, Merck KGaA

16.15
Close of Conference Day 1